{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigvsrjxiluk3yl7yw67cajjpbcewzgmwsybgub6o6v3anqxca6okm",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3ml4hsulg63d2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaifovzkbxji66ylvyotlslxb4nz5urp6tip3eolmfrcuhm5h2aqe"
    },
    "mimeType": "image/jpeg",
    "size": 118286
  },
  "path": "/news/2026-05-surveys-dysfunctional-gene-splicing-metastatic.html",
  "publishedAt": "2026-05-05T11:00:08.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Researchers at City of Hope and TGen (part of City of Hope) have identified a significant correlation between a tumor's \"splicing burden\" and its clinical response to treatment for metastatic renal cell carcinoma (mRCC). In a study published in the Journal for ImmunoTherapy of Cancer, researchers demonstrate that patients whose tumor tissue exhibits a high frequency of aberrant gene splicing are more likely to respond to therapy compared to those with fewer aberrant splicing events.",
  "title": "Study surveys dysfunctional gene splicing in metastatic kidney disease"
}